Treating as early as possible with thrombolysis is crucial, but can we do better in the sub-4.5-hour time window?

Cerebrovascular Diseases

Volumn 31, Issue 3, 2011, Pages 229-

  Parsons, Mark W ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CANADA; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DIFFUSION WEIGHTED IMAGING; DISEASE REGISTRY; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; HUMAN; MORTALITY; NOTE; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; STROKE PATIENT;

BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79951813221     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322555     Document Type: Note

References (7)

1. Shobha N, Buchan AM, Hill MD; on behalf of Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis at 3-4.5 hours after acute ischemic stroke onset - evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-228.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
3. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P; for the SITS investigators: Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9: 866-874.
4. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
5. Parsons MW, Christensen S, McElduff P, Levi CR, Butcher KS, De Silva DA, Ebinger M, Barber PA, Bladin C, Donnan GA, Davis SM; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators: Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab 2010; 30: 1214-1225.
6. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW: The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 2009; 132: 2231-2238.
7. De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS, Levi CR, Parsons MW, Bladin CF, Donnan GA, Davis SM; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators: The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke 2010; 41: 295-299.